LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions

Stephen V. Liu, Liza C. Villaruz, Victor Lee, Viola W. Zhu, Christina S. Baik, Adrian G. Sacher, Caroline E. McCoach, Danny Nguyen, J.Y-C. Li, J. Pacheco, Chul Kim, Timothy F. Burns, Erin L. Schenk, Natasha B. Leighl, Lorenzo Tozzi, D. Ross Camidge

2020Annals of Oncology82 citationsDOI

Topics & Concepts

MedicineCohortInternal medicineOncologyLung cancerProgressive diseaseResponse Evaluation Criteria in Solid TumorsKRASClinical endpointErbBChemotherapyCancerGastroenterologyClinical trialColorectal cancerCancer, Hypoxia, and MetabolismLung Cancer Treatments and MutationsLung Cancer Research Studies

LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations &amp; other solid tumours with NRG1/ERBB gene fusions

Topics & Concepts

LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions